Dr Adam Ritchie

Contact information

Email
adam.ritchie@ndm.ox.ac.uk

Telephone
01865 617623

Address
Old Road Campus Research Build (ORCRB), Roosevelt Drive, Oxford OX3 7DQ

Research groups

Adam Ritchie

BSc, PhD, FHEA

Senior Vaccinologist

Douglas Group

Adam is a Senior Vaccinologist at the Jenner Institute. He is currently focused on the rabies, EBV and COVID-19 vaccine projects, alongside work on policy and regulation as part of Vax-Hub Global. Adam's interest is on translation of academic research into real world impact through the efficient development, manufacture, and clinical testing of vaccine candidates.

Adam works includes the design and delivery of early phase clinical trials, regulatory affairs, public policy, and vaccine manufacturing.

Adam is also a Lecturer in Human Science at St Catherine's College.

Key publications

Development and Evaluation of Compact Semi-Synthetic Promoters for Enhanced Antigen Expression in Adenoviral-Vectored Vaccines

Hlaváč M. et al, (2026), Vaccines, 14, 260 - 260

Protocol for precision cutting and short-term culture of lymph node tissue slices for modeling of innate immune responses ex vivo.

Fergusson JR. et al, (2026), STAR Protoc, 7

Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B

Kalafateli M. et al, (2026), Clinical Gastroenterology and Hepatology, 24, 701 - 712.e8

Machine learning-driven identification of serotype-independent pneumococcal vaccine candidates using samples from human infection challenge studies

Cheliotis KS. et al, (2026), Vaccine, 75, 128280 - 128280

Modelling catastrophic extinction in stochastic birth-death process: Analytical insights, estimation, and efficient simulation

Twumasi C., (2026), Computational Statistics & Data Analysis, 215, 108302 - 108302

The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trial

Liatsikos K. et al, (2026), The Lancet Microbe, 7, 101267 - 101267

Structure-guided design of a PfCyRPA-based vaccine against blood-stage malaria.

Alam N. et al, (2026), EMBO molecular medicine

The age-specific concentrations and seroprevalence of antibodies against Salmonella Enteritidis (O:9) and Salmonella Typhimurium (O:4,5) across three sites in Kenya.

Muthumbi EM. et al, (2026), The Journal of infectious diseases

Longitudinal Epidemiology and Variant Dynamics of SARS-CoV-2 in Coastal Kenya (2020–2025): Clinical Features and Wave Patterns

Lambisia AW. et al, (2026), Open Forum Infectious Diseases

Predicting Salmonella Typhi incidence using prevalence metrics from sentinel studies of community-onset bloodstream infections

Hagedoorn N. et al, (2026)

Unsuppressed viraemia and lower CD4 count associated with faster telomere attrition in African children with perinatal HIV on long-term antiretroviral therapy.

Shellard JPG. et al, (2026), The Journal of infectious diseases

A risk to child health: confusion and concern over changes to US vaccine policy.

Pollard AJ. and Plotkin S., (2026), Lancet (London, England), 407, 553 - 556

SARS-CoV-2-Specific Immune Responses to Vaccination in Children and Adolescents with Suppressed Immune Systems: A Prospective, Observational Study.

Brugha R. et al, (2026), The Journal of pediatrics, 289

Eight-Year Vaccine Protection Following a Single Dose of VI-Tetanus Toxoid Conjugate Vaccine in Nepali Children: Extended Follow-Up of the TyVAC Nepal Randomised Controlled Trial

Pant D. et al, (2026)

Association between COVID-19 vaccine immunogenicity and protection against infection and severe disease in clinically vulnerable patient populations: a systematic review and meta-analysis of observational studies

Danysz M. et al, (2026), Clinical Microbiology and Infection, 32, 41 - 55

Impact of Dosing Interval on Immunogenicity Following a Heterologous Typhoid Conjugate Vaccine Booster in Nepalese Children: An Observational Study

Zhang Y. et al, (2026)

Phase II multicentre double-blind randomised controlled trial of a Bivalent VaccInation against Salmonella Typhi and Paratyphi A (BiVISTA) using a controlled human infection model of paratyphoid A infection: study protocol

Paganotti Vicentine M. et al, (2026), BMJ Open, 16, e107608 - e107608

Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial

Kapulu MC. et al, (2026), Nature Medicine, 32, 178 - 185

PD-1 blockade enhances functional vaccine-induced HIV-1 CD8+ T-cell responses in PWH receiving early ART

Marin M. et al, (2026), eBioMedicine, 123, 106070 - 106070

Uteroplacental detachment on transvaginal ultrasound is associated with substantial antepartum hemorrhage requiring early delivery in high-risk placenta accreta spectrum cases

Aryananda RA. et al, (2026), American Journal of Obstetrics and Gynecology, 233, S701 - S710

Persistence of Immune Responses 5 Years After Vaccination With a Single Dose of Typhoid Conjugate Vaccine (TCV) in Nepalese Children

Pant D. et al, (2026)

Time to tackle vaccine-HLA associations with artificial intelligence.

Mentzer AJ. et al, (2026), The Lancet. Infectious diseases, 26

Public attitudes towards intranasal and ultrasound mediated vaccine delivery: A cross-sectional study in the United Kingdom and United States.

Kantor J. et al, (2026), Vaccine, 69

Bromodomain and extra-terminal protein inhibitors modulate natural killer cell function and differentiation.

Geanes ES. et al, (2026), Scientific reports, 16

Longitudinal analysis of neutralizing antibodies against SARS-CoV-1 and different SARS-CoV-2 strains in breakthrough and unvaccinated COVID-19 patients in Thailand (2021-2022).

Poolchanuan P. et al, (2026), Scientific reports, 16

Pre-COVID-19 ex vivo cross-reactive IFN-γ cellular response to SARS-CoV-2 spike overlapping peptides is more prevalent among Kenyan compared to Swedish adults.

Wanjiku P. et al, (2026), BMC infectious diseases

Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial.

Kelly E. et al, (2026), The Journal of infection, 92

Public attitudes towards intranasal and ultrasound mediated vaccine delivery: A cross-sectional study in the United Kingdom and United States.

Kantor J. et al, (2026), Vaccine, 69

Corrigendum to "Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM" [Vaccine 68 (2025) 127897].

Mukhopadhyay ES. et al, (2026), Vaccine, 69

Replication-incompetent viral vaccine vectors ChAdOx1 and MVA as tools for evaluating T-cell responses to naturally processed antigens in vitro.

Nazki S. et al, (2026), Virus research, 364

A new era of coccidiosis control: Eimeria and Clostridium perfringens dynamics in vaccinated broiler flocks after the ionophore phase-out in Norway.

Estensmo EL. et al, (2026), Preventive veterinary medicine, 248

Heterologous mucosal vaccine boosting enhances mucosal and systemic immunity by distinct mechanisms.

Bissett C. et al, (2026), The Journal of experimental medicine, 223

The immunology of infection

Gilchrist JJ. et al, (2026), Medicine United Kingdom, 54, 1 - 8

Development and validation of the Oxford Benchmark Scale for Rating Vaccine Technologies (OBSRVT), a scale for assessing public attitudes to next-generation vaccine delivery technologies

Kantor J. et al, (2025), Human Vaccines & Immunotherapeutics, 21

Phase 1b/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-risk Human Papillomavirus Vaccine in Women With Low-grade Cervical Lesions

Hellner K. et al, (2025), Clinical Infectious Diseases

Modeling Indirect Protection from Typhoid Conjugate Vaccines in the TyVAC-Bangladesh Trial

Walker J. et al, (2025)

Recent publications

Routine childhood rabies pre-exposure prophylaxis can be cost effective in low- and middle-income countries.

Ritchie AJ. et al, (2025), Vaccine, 47

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

Madhavan M. et al, (2022), eBioMedicine, 85, 104298 - 104298

Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial

Jenkin D. et al, (2022), The Lancet Microbe, 3, e663 - e671

Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.

Joe CCD. et al, (2022), Biotechnology and bioengineering, 119, 48 - 58

Publisher Correction: Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.

Dulal P. et al, (2021), Scientific reports, 11

Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.

Dulal P. et al, (2021), Scientific reports, 11

Making THE vaccine

Joe CCD. and Ritchie AJ., (2021), Biochemist, 43, 8 - 13

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Voysey M. et al, (2021), The Lancet, 397, 881 - 891

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey M. et al, (2021), The Lancet, 397, 99 - 111

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478

Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation

Dulal P. et al, (2020)

Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components

Fedosyuk S. et al, (2019), Vaccine, 37, 6951 - 6961